Acadia Pharmaceuticals Q4 revenue rises 9% yr/yr

Acadia Pharmaceuticals

25/02/2026 21:56

Overview

Pharmaceutical firm's Q4 GAAP revenue up 9% yr/yr to $284 mln

Non-GAAP adjusted Q4 revenue rises 16% yr/yr to $298 mln

Company reports Q4 net income of $274 mln, up from $144 mln last year

Outlook

Company expects full-year 2026 total revenues of $1.22 bln to $1.28 bln

Acadia projects 2026 NUPLAZID net sales between $760 mln and $790 mln

Company anticipates DAYBUE net sales of $460 mln to $490 mln for 2026

Result Drivers

NUPLAZID VOLUME GROWTH - Co reported 13% increase in NUPLAZID volume for Q4, despite IRA rebate adjustments

DAYBUE SALES GROWTH - DAYBUE Q4 sales rose 13% yr/yr, driven by expanding reach and named patient supply programs

Company press release: ID:nBw6v7Dsxa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$283.99 mln
Q4 EPS
$1.60
Q4 Net Income
$273.57 mln
Q4 Operating Expenses
$266.60 mln
Q4 Pretax Profit
$26.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $32.00, about 30.1% above its February 24 closing price of $24.59

The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 28 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)